A Phase Ib Study of HS-10504 Combined Therapy in NSCLC
ConditionLung Cancer
Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-75
SponsorJiangsu Hansoh Pharmaceutical Co., Ltd.
About this trial
This is a multi-center, open-label, phase I study to evaluate the safety, efficacy, pharmacokinetics (PK), and immunogenicity of HS-10504 combined therapy in subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC).
Eligibility criteria
Qualifiers
Cohort1:participants with EGFR mutation advanced stage NSCLC，disease progression on or after prior treatment；
Cohort2:participants with MET position advanced stage NSCLC，disease progression on or after prior treatment；
With at least 1 target lesion according to RECIST 1.1.
Appropriate organ function
Disqualifiers
Insufficient wash out duration of prior systemic anticancer therapy
Local radiotherapy within 2 weeks prior to first dose of investigational drug
Pleural/abdominal effusion requires clinical intervention
Major surgery within 4 weeks prior to first dose of investigational drug
Trial design
Treatments tested in this trial
- HS-10504
- SHR-A2009
- HS-20122
- HS-20117
- SHR-1826
- SHR-A2102
Treatment groups
400 Participants
are divided into 5 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov